全文获取类型
收费全文 | 10695篇 |
免费 | 843篇 |
国内免费 | 620篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 53篇 |
妇产科学 | 77篇 |
基础医学 | 524篇 |
口腔科学 | 130篇 |
临床医学 | 513篇 |
内科学 | 537篇 |
皮肤病学 | 296篇 |
神经病学 | 122篇 |
特种医学 | 229篇 |
外国民族医学 | 1篇 |
外科学 | 339篇 |
综合类 | 1717篇 |
预防医学 | 1256篇 |
眼科学 | 525篇 |
药学 | 2847篇 |
6篇 | |
中国医学 | 2604篇 |
肿瘤学 | 351篇 |
出版年
2024年 | 15篇 |
2023年 | 150篇 |
2022年 | 231篇 |
2021年 | 359篇 |
2020年 | 356篇 |
2019年 | 308篇 |
2018年 | 300篇 |
2017年 | 352篇 |
2016年 | 400篇 |
2015年 | 356篇 |
2014年 | 696篇 |
2013年 | 800篇 |
2012年 | 824篇 |
2011年 | 856篇 |
2010年 | 650篇 |
2009年 | 576篇 |
2008年 | 541篇 |
2007年 | 602篇 |
2006年 | 458篇 |
2005年 | 400篇 |
2004年 | 371篇 |
2003年 | 310篇 |
2002年 | 230篇 |
2001年 | 243篇 |
2000年 | 189篇 |
1999年 | 186篇 |
1998年 | 160篇 |
1997年 | 131篇 |
1996年 | 141篇 |
1995年 | 124篇 |
1994年 | 137篇 |
1993年 | 103篇 |
1992年 | 76篇 |
1991年 | 56篇 |
1990年 | 70篇 |
1989年 | 64篇 |
1988年 | 57篇 |
1987年 | 42篇 |
1986年 | 43篇 |
1985年 | 42篇 |
1984年 | 28篇 |
1983年 | 30篇 |
1982年 | 22篇 |
1981年 | 15篇 |
1980年 | 14篇 |
1979年 | 7篇 |
1978年 | 11篇 |
1977年 | 10篇 |
1976年 | 5篇 |
1975年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1213-1221.e5
PurposeTo investigate the pharmacokinetics (PK) and early effects of conventional transarterial chemoembolization (TACE) using sorafenib and doxorubicin on tumor necrosis, hypoxia markers, and angiogenesis in a rabbit VX2 liver tumor model.Materials and MethodsVX2 tumor-laden New Zealand White rabbits (N = 16) were divided into 2 groups: 1 group was treated with hepatic arterial administration of ethiodized oil and doxorubicin emulsion (DOX-TACE), and the other group was treated with ethiodized oil, sorafenib, and doxorubicin emulsion (SORA-DOX-TACE). Animals were killed within 3 days of the procedure. Levels of sorafenib and doxorubicin were measured in blood, tumor, and adjacent liver using mass spectrometry. Tumor necrosis was determined by histopathological examination. Intratumoral hypoxia-inducible factor (HIF) 1α, vascular endothelial growth factor (VEGF), and microvessel density (MVD) were determined by immunohistochemistry.ResultsThe median intratumoral concentration of sorafenib in the SORA-DOX-TACE group was 17.7 μg/mL (interquartile range [IQR], 7.42–33.5 μg/mL), and its maximal plasma concentration (Cmax) was 0.164 μg/mL (IQR, 0.0798–0.528 μg/mL). The intratumoral concentration and Cmax of doxorubicin were similar between the groups: 4.08 μg/mL (IQR, 3.18–4.79 μg/mL) and 0.677 μg/mL (IQR, 0.315–1.23 μg/mL), respectively, in the DOX-TACE group and 1.68 μg/mL (IQR, 0.795–4.08 μg/mL) and 0.298 μg/mL (IQR, 0.241–0.64 μg/mL), respectively, in the SORA-DOX-TACE group. HIF-1α expression was increased in the SORA-DOX-TACE group than in the DOX-TACE group. Tumor volume, tumor necrosis, VEGF expression, and MVD were similar between the 2 groups.ConclusionsThe addition of sorafenib to DOX-TACE delivered to VX2 liver tumors resulted in high intratumoral and low systemic concentrations of sorafenib without altering the PK of doxorubicin. 相似文献
2.
Defects of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein affect the homeostasis of chloride, bicarbonate, sodium, and water in the airway surface liquid, influencing the mucus composition and viscosity, which induces a severe condition of infection and inflammation along the whole life of CF patients. The introduction of CFTR modulators, novel drugs directly intervening to rescue the function of CFTR protein, opens a new era of experimental research. The review summarizes the most recent advancements to understand the characteristics of the infective and inflammatory pathology of CF lungs. 相似文献
3.
4.
In forensic medicine, although various alcohols have been reported as indicators of decomposition in collected blood, no studies have examined short-chain fatty acids as indicators. In this study, the blood n-butyric acid concentration was quantified, and the association between n-butyric acid and decomposition was investigated to determine whether the detection of n-butyric acid could be a new indicator of decomposition. Among the forensic autopsies performed from 2016 to 2018 in our laboratory, the cases were divided into decomposed (n = 20) and non-decomposed (n = 20) groups based on macroscopic findings. Blood samples collected at the time of autopsy were derivatized with 3-nitrophenylhydrazine hydrochloride after solid-phase extraction. The n-butyric acid concentration was measured using liquid chromatography–tandem mass spectrometry. In addition, ethanol and n-propanol were measured using a gas chromatography-flame ionization detector. There was a significant difference (p < 0.01) in the concentrations of n-butyric acid between the decomposed and non-decomposed groups (0.343 ± 0.259 [0.030–0.973] and 0.003 ± 0.002 [0.001–0.007] mg/mL, respectively). In the decomposed group, n-butyric acid was detected at high concentrations, even in cases where n-propanol was low. These results suggest that n-butyric acid is more likely to be an indicator of blood decomposition than n-propanol. 相似文献
5.
生姜炮制成干姜前后挥发油透皮吸收促进作用的比较研究 总被引:1,自引:0,他引:1
目的 比较生姜炮制成干姜前后挥发油透皮吸收促进作用及成分的变化。方法 将生姜炮制成干姜前后提取挥发油,皮肤电阻动力学实验和体外布洛芬透皮实验比较二者的促渗能力,ATR-FTIR红外分析挥发油透皮促渗主要机制,皮肤细胞毒性实验比较了生姜和干姜挥发油的细胞毒性,GC-MS分析成分变化。结果 干姜挥发油的透皮吸收促进作用显著优于生姜挥发油,其透皮促渗机制主要为对皮肤角质层脂质的萃取,而生姜和干姜挥发油的皮肤细胞毒性均显著低于化学促渗剂氮酮,炮制后干姜挥发油的倍半萜类成分比例高于生姜挥发油,透皮后干姜挥发油组皮内的倍半萜类成分比例也高于生姜挥发油组。结论 炮制后的干姜挥发油的透皮吸收作用优于生姜挥发油,验证了中药挥发油透皮吸收促进剂存在"热者易效"的规律。 相似文献
6.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(10):1030-1039
Background and aimThis network meta-analysis (NMA) compares the effects of different types of olive oil (OO) on cardiovascular risk factors.Methods and resultsLiterature search was conducted on three electronic databases (Medline, Web of Science, and Cochrane Central). Inclusion criteria: Randomized controlled trials (RCTs) (≥3 weeks duration of intervention) comparing at least two of the following types of OO: refined OO (ROO), mixed OO (MOO), low phenolic (extra) virgin OO (LP(E)VOO), and high phenolic (extra) virgin OO (HP(E)VOO). Random-effects NMA was performed for seven outcomes; and surface under the cumulative ranking curve (SUCRA) was estimated, using an analytical approach (P-score). Thirteen RCTs (16 reports) with 611 mainly healthy participants (mean age: 26–70 years) were identified. No differences for total cholesterol, HDL-cholesterol, triacylglycerols, and diastolic blood pressure were observed comparing ROO, MOO, LP(E)VOO and HP(E)VOO. HP(E)VOO slightly reduce LDL-cholesterol (LDL-C) compared to LP(E)VOO (mean difference [MD]: −0.14 mmol/L, 95%–CI: −0.28, −0.01). Both, HP(E)VOO and LP(E)VOO reduces SBP compared to ROO (range of MD: −2.99 to −2.87 mmHg), and HP(E)VOO may improve oxidized LDL-cholesterol (oxLDL-C) compared to ROO (standardized MD: −0.68, 95%–CI: −1.31, −0.04). In secondary analyses, EVOO may reduce oxLDL-C compared to ROO, and a dose-response relationship between higher intakes of phenolic compounds from OO and lower SBP and oxLDL-C values was detected. HP(E)VOO was ranked as best treatment for LDL-C (P-score: 0.83), oxLDL-C (0.88), and SBP (0.75).ConclusionsHP(E)VOO may improve some cardiovascular risk factors, however, public health implications are limited by overall low or moderate certainty of evidence. 相似文献
7.
Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity.Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility.Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer’s (BC) characterization and treatment. 相似文献
8.
《Clinical lung cancer》2020,21(6):545-552.e1
BackgroundOutcomes of therapy targeting molecular driver alterations detected in advanced non–small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive.Patients and MethodsWe performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up.ResultsSeventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting.ConclusionsPatients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment. 相似文献
9.
10.
目的 总结中美权威机构推荐的结直肠癌筛查手段。方法 在美国预防医学工作组(USPSTF)、美国纽约州卫生部、国家消化系统疾病临床医学研究中心等权威机构网站检索 “结直肠癌”、“筛查”等关键词。根据权威机构推荐的早期筛查方法,进一步在NCBI数据库中检索获得技术实施方法、优缺点等信息。结果 比较了结肠镜、结肠CT、钡灌肠造影、粪便隐血试验、粪便免疫化学试验、粪便DNA检测和液体活检的敏感性、特异性及优缺点。结论 内镜及影像技术不断完善。各种非侵入性、高敏感性、高特异性的生物标志物不断涌现,并需及早开展临床试验,以满足大规模人群筛查的需求。 相似文献